Lumexa Imaging's Dr. Kemp Joins RSNA Board

Written by Emily J. Thompson, Senior Investment Analyst

LMRI0%

Source: PRnewswire

Updated: 2h ago

0mins

Source: PRnewswire

Leadership Change: Dr. Jennifer L. Kemp, Chair of Lumexa Imaging's Center for Quality, has been elected to the Board of Directors of the Radiological Society of North America, reflecting the company's clinical leadership and the vital role of physicians in radiology.
Patient Experience Enhancement: In her role as Chief of Patient Experience at Scanslated, Dr. Kemp leads initiatives to improve patient understanding of radiology results, showcasing the company's commitment to innovation in patient engagement.
Technology Platform Utilization: Lumexa Imaging has utilized Scanslated's AI-driven software to provide over 2 million patients with clear radiology reports, significantly enhancing their likelihood of choosing Lumexa Imaging centers in the future.
Industry Development Commitment: Dr. Kemp's role at RSNA will help guide the future of radiology, ensuring high-quality patient care while strengthening the voice of radiologists, aligning with Lumexa Imaging's commitment to clinical excellence and patient experience.

LMRI

$13.83+Infinity%1D

Analyst Views on LMRI

Wall Street analysts forecast LMRI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LMRI is 22.71 USD with a low forecast of 22.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Analyst Rating

8 Buy

0 Hold

0 Sell

Strong Buy

Current: 13.830

Low

22.00

Averages

22.71

High

23.00

Current: 13.830

Low

22.00

Averages

22.71

High

23.00

Deutsche Bank

NULL -> Buy

initiated

$22

2026-01-05

Reason

Deutsche Bank

Price Target

$22

AI Analysis

2026-01-05

initiated

NULL -> Buy

Reason

Deutsche Bank initiated coverage of Lumexa Imaging with a Buy rating and $22 price target. The firm says Lumexa is the second-largest independent diagnostic testing facility operator in the U.S. The company's growth drivers include share gains versus hospital outpatient via referral channels and direct-to-consumer marketing as well as an increasing advanced imaging mix, the analyst tells investors in a research note.

Barclays

Overweight

initiated

$23

2026-01-05

Reason

Barclays

Price Target

$23

2026-01-05

initiated

Overweight

Reason

Barclays initiated coverage of Lumexa Imaging with an Overweight rating and $23 price target. The firm likes the company's strong local market positions and accelerating new center openings. Lumexa benefits from rising demand for diagnostic imaging due to increasing chronic diseases and the shift to lower-cost care sites,the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for LMRI

Unlock Now

Jefferies

NULL -> Buy

initiated

$23

2026-01-05

Reason

Jefferies

Price Target

$23

2026-01-05

initiated

NULL -> Buy

Reason

Jefferies initiated coverage of Lumexa Imaging with a Buy rating and $23 price target. The company is well positioned for 8%-9% EBITDA growth annually over the next five years, the analyst tells investors in a research note. The firm believes Lumexa will benefit from secular tailwinds in imaging, the opening of new clinics, the ramp of facilities opened in the last few years, and rate growth.

Wells Fargo

Overweight

initiated

$22

2026-01-05

Reason

Wells Fargo

Price Target

$22

2026-01-05

initiated

Overweight

Reason

Wells Fargo initiated coverage of Lumexa Imaging with an Overweight rating and $22 price target. The company offers "attractive growth" in an end market with tailwinds due to lower cost of services and better experience for patients, the analyst tells investors in a research note. Wells says Lumexa is one of the largest providers of outpatient imaging services in the U.S. Imaging overall has solid demand and growth characteristics, the firm contends.

About LMRI

Lumexa Imaging Holdings, Inc. is a national provider of diagnostic imaging services. The Company offers a range of advanced imaging services (MRI, CT and PET scans) and routine diagnostic and screening imaging services (X-ray, ultrasound and mammography). The Company’s segments include Outpatient Imaging Centers (Outpatient) and Professional Services (Professional). The Outpatient segment consists of imaging centers that are owned or operated by it (either wholly owned or via unconsolidated affiliate), where it performs the imaging scan and provides the radiologist’s interpretation service. The Professional segment consists of professional interpretation services, where the imaging scan itself is performed at the hospital or point of care and not by it or its unconsolidated affiliates. The Company and its affiliates operate outpatient imaging center footprint in the United States, spanning 184 centers across 13 states and includes eight joint venture partnerships with health systems.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.